Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
November 17, 2023 07:00 ET
|
Day One Biopharmaceuticals, Inc.
BRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and...
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023 08:00 ET
|
Day One Biopharmaceuticals, Inc.
BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and...
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
November 06, 2023 16:30 ET
|
Day One Biopharmaceuticals, Inc.
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 30, 2023 08:00 ET
|
Day One Biopharmaceuticals, Inc.
The FDA has granted priority review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024.
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
September 11, 2023 21:02 ET
|
Day One Biopharmaceuticals, Inc.
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment ...
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
September 11, 2023 08:30 ET
|
Day One Biopharmaceuticals, Inc.
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment ...
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
August 16, 2023 08:00 ET
|
Day One Biopharmaceuticals, Inc.
Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One’s portfolio of...
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
August 07, 2023 16:30 ET
|
Day One Biopharmaceuticals, Inc.
Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG)...
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 12, 2023 08:00 ET
|
Day One Biopharmaceuticals, Inc.
BRISBANE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...
Day One Announces Pricing of Public Offering of Common Stock
June 06, 2023 22:31 ET
|
Day One Biopharmaceuticals, Inc.
BRISBANE, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...